High surface-area lyophilized compositions comprising arsenic for oral administration in patients
The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.
1. A solution for use in the lyophilization of a pharmaceutical compound comprising:
an amount of water;
an amount of solubilized arsenic trioxide;
an amount of solubilized alkalizing agent;
an amount of solubilized surfactant; and,
an amount of an acid;
wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 6 mg/mL to about 50 mg/mL.
2. The solution of claim 1 , wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 6 mg/ml to about 25 mg/ml.
3. The solution of claim 1 , wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 11 mg/ml to about 50 mg/ml.
4. The solution of claim 1 , wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 11 mg/ml to about 25 mg/ml.
5. The solution of claim 1 , wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 23 mg/ml to about 50 mg/ml.
6. The solution of claim 1 , wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 23 mg/ml to about 25 mg/ml.
7. The solution of claim 1 , wherein the weight ratio of the amount of solubilized arsenic trioxide to the amount of solubilized alkalizing agent is in the range of about 10:1 to 1:1.
8. The solution of claim 1 , wherein the weight ratio of the amount of solubilized arsenic trioxide to the amount of solubilized alkalizing agent is in the range of about of 2:1 to 1:1.
9. The solution of claim 1 , wherein the weight ratio of the amount of solubilized arsenic trioxide to the amount of solubilized surfactant is in the range of about 10:1 to 2:1.
10. The solution of claim 1 , wherein the amount of solubilized surfactant is present in the solution in the range of 0.5% to 4.0% v/v of the solution.
11. The solution of claim 1 , wherein the amount of solubilized alkalizing agent and the amount of the acid in the solution provides a pH in the range of about 7.0 to 8.2.
12. The solution of claim 1 , wherein the solubilized alkalizing agent is sodium hydroxide, sodium carbonate, or a mixture thereof.
13. The solution of claim 1 , wherein the solubilized surfactant is sodium lauryl sulfate; polyoxyethylene sorbitan monooleate; betacyclodextrin; poloxamer; tocopheryl polyethylene glycol succinate (TPGS).
14. The solution of claim 1 , wherein the solubilized alkalizing agent is sodium hydroxide and the solubilized surfactant is sodium lauryl sulfate.
15. The solution of claim 1 wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 11 mg/ml to about 50 mg/ml, and wherein the weight ratio of the amount of solubilized arsenic trioxide to the amount of solubilized alkalizing agent is in the range of about of 2:1 to 1:1.
16. The solution of claim 1 wherein the amount of solubilized arsenic trioxide is present in the solution at a concentration level of about 11 mg/ml to about 50 mg/ml, and wherein the weight ratio of the amount of solubilized arsenic trioxide to the amount of solubilized surfactant is in the range of about 10:1 to 2:1.